HGF stimulates proliferation through the HGF/c-Met pathway in nasopharyngeal carcinoma cells

Sun,Rui; Zhang,Qing; Guo,Ling; Chen,Ming-Yuan; Sun,Ying; Cao,Brian; Sun,Jian

doi:10.3892/ol.2012.613

HGF stimulates proliferation through the HGF/c-Met pathway in nasopharyngeal carcinoma cells

Authors:
- Rui Sun
- Qing Zhang
- Ling Guo
- Ming-Yuan Chen
- Ying Sun
- Brian Cao
- Jian Sun
View Affiliations

Affiliations: State Key Laboratory of Oncology in Southern China, Sun Yat-sen University, Guangzhou 510060, P.R. China, Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, P.R. China, Van Andel Research Institute, Grand Rapids, MI 49503, USA, Cancer Center, Sun Yat-sen University, Guangzhou 510060, P.R. China
Published online on: February 20, 2012 https://doi.org/10.3892/ol.2012.613
Pages: 1124-1128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocyte growth factor (HGF) and its receptor c-Met are important in the development and homeostasis of a variety of human malignancies. However, the role of the HGF/c-Met signaling pathway in nasopharyngeal carcinoma (NPC) has not been clearly elucidated. This study examined the effect of HGF/c-Met on proliferation and migration in several NPC cell lines. RT-PCR was used to detect the HGF gene in CNE-1, CNE-2, HK-1, HONE-1 and SUNE-1 NPC cells. However, HGF gene expression was not detected in any of these cells. Using immunoblotting analysis, the Met25 protein was identified in HONE-1, HK-1 and CNE-1 cells. Results from fluorescence‑activated cell sorting (FACS) analysis revealed that anti-Met25 mAb specifically bound Met-expressing HONE-1, HK-1 and CNE-1 cells. It was further demonstrated that exogenous HGF was able to stimulate the proliferation of HONE-1 and HK-1 cells and the healing of scrape wounds in HONE-1 NPC cells. Our results reveal the potential therapeutic applications of combination therapy with antibodies targeting HGF in NPC patients.

View Figures

View References

1	Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C and Armand JP: Nasopharyngeal carcinoma: an update. Eur J Cancer. 39:2121–2135. 2003. View Article : Google Scholar : PubMed/NCBI
2	Lai SZ, Li WF, Chen L, et al: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 80:661–668. 2011. View Article : Google Scholar
3	Lee AW, Ng WT, Hung WM, et al: Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors. Int J Radiat Oncol Biol Phys. 73:1121–1128. 2009. View Article : Google Scholar : PubMed/NCBI
4	Chan AT, Leung SF, Ngan RK, et al: Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 97:536–539. 2005. View Article : Google Scholar
5	Wei KR, Xu Y, Liu J, Zhang WJ and Liang ZH: Histopathological classification of nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 12:1141–1147. 2011.PubMed/NCBI
6	Trusolino L and Comoglio PM: Scatter-factor and semaphoring receptors: cell signalling for invasive growth. Nat Rev Cancer. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
7	Qian CN, Guo X, Cao B, et al: Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 62:589–596. 2002.PubMed/NCBI
8	Rong S, Oskarsson M, Faletto D, et al: Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human Met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ. 4:563–569. 1993.PubMed/NCBI
9	Jeffers M, Rong S and Vande Woude GF: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol. 16:1115–1125. 1996.
10	Cao B, Su Y, Oskarsson M, et al: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA. 98:7443–7448. 2001. View Article : Google Scholar
11	Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J and Au GK: Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck. 30:863–867. 2008. View Article : Google Scholar : PubMed/NCBI
12	Eder JP, Vande Woude GF, Boerner SA and LoRusso PM: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15:2207–2214. 2009. View Article : Google Scholar : PubMed/NCBI
13	Arriola E, Cañadas I, Arumí-Uría M, et al: MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer. 105:814–823. 2011. View Article : Google Scholar : PubMed/NCBI
14	Syed ZA, Yin W, Hughes K, Gill JN, Shi R and Clifford JL: HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer. 11:1802011. View Article : Google Scholar : PubMed/NCBI
15	Xie LQ, Bian LJ, Li Z, Li Y, Li ZX and Li B: Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol. 17:1927–1936. 2010. View Article : Google Scholar : PubMed/NCBI
16	Aune G, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE and Stunes AK: Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol. 121:402–406. 2011. View Article : Google Scholar : PubMed/NCBI
17	Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H and Kusunoki M: Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol. 39:754–760. 2004. View Article : Google Scholar : PubMed/NCBI
18	Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K and Kusunoki M: Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 125:1657–1662. 2009. View Article : Google Scholar : PubMed/NCBI
19	Mizuguchi T, Nagayama M, Meguro M, et al: Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg. 13:325–333. 2009. View Article : Google Scholar